FindTrial
Sign In

Predictions of outcome and toxicity of stereotactic ablative radiotherapy for malignant pulmonary nodules using artificial intelligence

Predictions of outcome and toxicity of stereotactic ablative radiotherapy for malignant pulmonary nodules using artificial intelligence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066757
Enrollment
Unknown
Registered
2022-12-15
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:not applicable

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) old than 18 years old (2) pathological diagnosis of malignant pulmonary nodules (PN) (3) radiological diagnosis of maligant PN but cannot or refused to conduct biopsy (4) refuse surgery or unsuitable for surgery (5) older patients such as >60 years old who refuse or cannot undergo surgery (6) KPS >=70 (7) single or multiple PN who are suitable for SBRT (8) primary or metastatic malignant PN who are suitable for SBRT (9) patients whose survival time longer than 3 months (10) patients who sign the consent form and agree to perform SBRT

Exclusion criteria

Exclusion criteria: (1) patients who are suitable for surgery or choose surgery (2) PNs are benign.

Design outcomes

Primary

MeasureTime frame
Local control;—

Countries

China

Contacts

Public ContactYuenan Wang

Peking University Shenzhen Hospital

yuenan_wang@163.com13554725783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026